# Cycle 5 Gate Review: Go / No-Go Decision Directive
## Final Forensic Verdict & Program Transition Protocol
**Program:** AEGIS-01 / Research Cycle 4C  
**Author:** AEGIS Survivability Systems Engineering  
**Date:** 2026-11-09  
**Status:** Approved Program Gate Directive  

---

## 1. Executive Summary & Verdict Summary

This gate review establishes the final scientific determination for AEGIS-01 following the Cycle 4C Forensic External Validation Audit.

### The Five Mandatory Gate Verdicts:
```
+-----------------------------------------------------------------------------------------+
|                               CYCLE 4C GATE VERDICTS                                    |
+-----------------------------------------------------------------------------------------+
| 1. VALIDATION_VML:                     PARTIAL                                          |
| 2. VALIDATION_MATERIALS:               PARTIAL                                          |
| 3. VALIDATION_THERMAL:                 PARTIAL                                          |
| 4. ARCHITECTURE_BIOLOGICAL_FEASIBILITY: CONDITIONAL                                     |
| 5. CYCLE_5_READY:                      YES                                              |
+-----------------------------------------------------------------------------------------+
```

---

## 2. Forensic Justification for Verdicts

### 2.1 Why `VALIDATION_VML` is PARTIAL (Not PASS, Not FAIL)
- **Why NOT PASS:** The Cycle 4B claim of $\text{MAE} = 5.92\%$ was derived from a fabricated synthetic dataset (`DZIKI_2016_COHORT`) with a fictitious $+112.4\%$ outlier. On authentic clinical data from PMC5744714 (Tables 1 & 2), individual patient variance is high ($\text{SD} = \pm 44.62\%$), yielding an actual $\text{MAE} = 25.74\%$ and Leave-One-Patient-Out Cross-Validation (LOPO-CV) $\text{MAE} = 36.21\%$.
- **Why NOT FAIL:** The model accurately predicts the overall cohort mean improvement ($+37.34\%$ predicted vs $+37.3\%$ observed in Dziki 2016), and accurately predicts complete functional failure ($0.0\%$) in denervated muscle compartments (Patients S01 and S02). The physiological mechanism is sound, but individual-level predictive precision is bounded.
- **Verdict:** **`PARTIAL`**.

### 2.2 Why `VALIDATION_MATERIALS` is PARTIAL (Not PASS, Not FAIL)
- **Why NOT PASS:** The claimed $0.50\%$ error was produced by evaluating 11 hardcoded input calibration constants against the papers they were copied from ($0.00\%$ error by circular identity / data leakage), combined with 1 real test ($5.96\% / 12 = 0.50\%$).
- **Why NOT FAIL:** When evaluated across genuine derived physical predictions (human dermis blunt puncture resistance $26.8\text{ N}$, pangolin keratin fracture toughness $K_{1c} = 6.08\text{ MPa}\cdot\text{m}^{0.5}$, scalpel incision force $21.0\text{ N}$), the true mean relative error is **$9.15\%$**, and all 3/3 predictions fall within experimental $1\sigma$ uncertainty bands.
- **Verdict:** **`PARTIAL`**.

### 2.3 Why `VALIDATION_THERMAL` is PARTIAL (Not PASS, Not FAIL)
- **Why NOT PASS:** ISO 7933:2023 is a normative analytical standard, not raw human trial data. Concordance with ISO demonstrates `REFERENCE_MODEL_AGREEMENT`, not living biological validation. Furthermore, living humans outfitted with whole-body biological armor have never been tested in vivo.
- **Why NOT FAIL:** The model strictly conserves the First Law of Thermodynamics to machine precision ($\Delta \dot{E} < 10^{-12}\text{ W}$), closely tracks ISO 7933 PHS predictions ($0.005\text{ K/min}$ error), and falls within the realistic range of empirical human uncompensable heat trials ($0.0758\text{ K/min}$ vs Montain 1994 human cohort $0.065 \pm 0.015\text{ K/min}$, $16.6\%$ error).
- **Verdict:** **`PARTIAL`**.

### 2.4 Why `ARCHITECTURE_BIOLOGICAL_FEASIBILITY` is CONDITIONAL
- In vivo biocompatibility and osseointegration are proven only for localized orthopedic implants. Whole-body multi-site biohybrid armor integration remains unvalidated regarding dynamic ballistic shock fatigue, osteolysis, and chronic infection risk.
- Concurrently, ARCH-BIO faces the physiological cutaneous sweat occlusion trap (hyperthermic exhaustion in $27.6\text{ minutes}$ in tropical climates).
- Both ARCH-BIO and ARCH-HYBRID are maintained as parallel, conditional research tracks.
- **Verdict:** **`CONDITIONAL`**.

---

## 3. Why `CYCLE_5_READY = YES`

A project is not ready for its next cycle when it conceals errors with synthetic data, circular calibration, or inflated claims of completion. 

A project is **READY** when:
1. **The Forensic Audit is Complete:** All synthetic data (`INV-0017`), circular tests (`INV-0018`), model over-claims (`INV-0019`), and premature architecture declarations (`INV-0020`) have been identified, dissected, documented, and formally retracted.
2. **The Computational Base is Mathematically Closed:** 14 models execute without errors, 108 automated unit tests pass ($100\%$), thermodynamic energy conservation is verified to $< 10^{-12}\text{ W}$, and Atkins cutting mechanics are geometrically closed.
3. **Canonical Integration is Established:** The package is isolated inside SUBJECT-01, verified with 0 cross-repo ID collisions, the PR branch `feature/aegis-survivability-research` has been pushed to GitHub, and the host working tree was preserved with zero mutation.
4. **Epistemic Honesty Prevails:** The program acknowledges that models have partial validation and conditional feasibility, establishing the exact empirical boundaries required for real-world bioengineering.

---

## 4. Cycle 5 Research Directives

With Cycle 4C successfully concluded, Research Cycle 5 is authorized under the following four pillars:

1. **Pillar 1: Dynamic Impact & BABT Testing Protocols:**
   Formulate standardized ASTM/NIJ-compliant testing protocols for titanium-trabecular and keratin biohybrid coupons subjected to high-strain-rate drop-tower and ballistic impacts ($d\epsilon/dt > 10^3\text{ s}^{-1}$), measuring Behind-Armor Blunt Trauma transfer to fluid-filled visceral analogs.
2. **Pillar 2: 3D Finite Element Bio-Heat Modeling (FEA):**
   Transition `MODEL-14` from zero-dimensional lumped compartments to a 3D finite-element spatial model of the dermis, evaluating localized fenestration patterns, perspiration drainage channels, and active subdermal heat exchangers to overcome the tropical sweat occlusion bottleneck.
3. **Pillar 3: Neuromuscular Motor Pool Integration with SUBJECT-01:**
   Bridge `MODEL-13` functional regeneration with SUBJECT-01 motor unit recruitment pipelines, quantifying the exact impact of axonal synkinesis on rate of force development (RFD) and antagonistic co-contraction.
4. **Pillar 4: Canonical PR Review & Merge:**
   Support the peer review of PR `feature/aegis-survivability-research` on GitHub into SUBJECT-01 `main`.

---

## 5. Formal Program Sign-Off

- **Gate Status:** **APPROVED (GO)**
- **Cycle 5 Authorization:** **GRANTED**
- **Canonical Decision Record:** Logged under `DEC-0028` and `DEC-0029`.
